Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells

Future Microbiology

Volumn 12, Issue 16, 2017, Pages 1449-1455

  Servi, Barbara De ^a   Ranzini, Francesco ^a  

^a In Vitro Research Laboratories   (Italy)

Author keywords

Acute gastroenteritis; diarrhea; Escherichia coli; gelatin tannate; inactivated probiotics; mucoprotectors

Indexed keywords

ANTIDIARRHEAL AGENT; GELATINE TANNATE PLUS PROBIOTIC AGENT; LUCIFER YELLOW; PROBIOTIC AGENT; SILICON DIOXIDE; TASECTAN DUO; UNCLASSIFIED DRUG; GELATIN; SILICATE; TANNATE GELATIN; TANNIN DERIVATIVE;

ARTICLE; BIFIDOBACTERIUM BIFIDUM; CACO-2 CELL LINE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; HT-29 CELL LINE; HT-29-MTX CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LACTOBACILLUS; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; TRANSEPITHELIAL RESISTANCE; BIOLOGICAL MODEL; CELL LINE; DIARRHEA; EPITHELIUM CELL; ESCHERICHIA COLI INFECTION; GOBLET CELL; MICROBIOLOGY; PHYSIOLOGY;

ANTIDIARRHEALS; CELL LINE; DIARRHEA; EPITHELIAL CELLS; ESCHERICHIA COLI INFECTIONS; GELATIN; GOBLET CELLS; HUMANS; MODELS, BIOLOGICAL; PERMEABILITY; PROBIOTICS; SILICATES; TANNINS;

EID: 85036610282     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2016-0195     Document Type: Article

References (25)

1. De Servi B, Ranzini F, Meloni M. Antidiarrhoeal agents and paracellular permeability of E. Coli-infected Caco-Goblet intestinal model. Novintethical www.vitroscreen.com/pdf/2013%20POSTER%20CACO-GOBLET GASTROENTEROLOGY.pdf
2. Esteban Carretero J, Durban Reguera F, Lopez-Argueta Alvarez S, Lopez Montes J. A comparative analysis of response to vs. ORS + gelatin tannate pediatric patients with acute diarrhea. Rev. Esp. Enferm. Dig. 101(1), 41-48 (2009).
3. Zhao H, Zhang H, Wu H, et al. Protective role of 1, 25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice. BMC Gastroenterol. 12, 57 (2012).
4. Allegrini A, Costantini M. TasectanTM (gelatine tannate) for the treatment of acute gastroenteritis in children: Preliminary results from a study conducted to evaluate its efficacy and safety.http://tasectan.ie/wp-content/uploads/2012/10/10.1-Poster-TASECTANT-Belgium March-20111.pdf
5. Ferruzza S, Rossi C, Scarino ML, Sambuy Y. A protocol for in situ enzyme assays to assess the differentiation of human intestinal Caco-2 cells. Toxicol. In Vitro 26(8), 1247-1251 (2012).
6. Ferruzza S, Rossi C, Scarino ML, Sambuy Y. A protocol for differentiation of human intestinal Caco-2 cells in asymmetric serum-containing medium. Toxicol. In Vitro 26(8), 1252-1255 (2012).
7. Prieto P, Hoffmann S, Tirelli V, et al. An exploratory study of two Caco-2 cell models for oral absorption: A report on their within-laboratory and between-laboratory variability, and their predictive capacity. Altern. Lab. Anim. 38(5), 367-386 (2010).
8. Angelis ID, Turco L. Caco-2 cells as a model for intestinal absorption. Curr. Protoc. Toxicol. Chapter 20, Unit 20-26 doi:10.1002/0471140856.tx2006s47 (2011) (Epub ahead of print).
9. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests. Mol. Pharm. 3(6), 686-694 (2006).
10. Pontier C, Pachot J, Botham R, et al. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: Role of the mucus layer. J. Pharm. Sci. 90(10), 1608-1619 (2001).
11. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: Permeabilities via diffusion, inside-A nd outside-directed carrier-mediated transport. J. Pharm. Sci. 89(1), 63-75 (2000).
12. Ruszczynski M, Urbanska M, Szajewska H. Gelatin tannate for treating acute gastroenteritis: A systematic review. Ann. Gastroenterol. 27(2), 121-124 (2014).
13. Bueno L, Sekkal S, Theodoru V, Dattilo M. OP249. Undissociated gelatine tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: Results from in vitro and in vivo studies. United European Gastroenterol. J. 1(Suppl. 1), A75-A76 (2013).
14. Lopetuso LR, Scaldaferri F, Bruno G, Petito V, Franceschi F, Gasbarrini A. The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors. Eur. Rev. Med. Pharmacol. Sci. 19(6), 1068-1076 (2015).
15. Michalek D, Kolodziej M, Konarska Z, Szajewska H. Efficacy and safety of gelatine tannate for the treatment of acute gastroenteritis in children: Protocol of a randomised controlled trial. BMJ Open 6(2), e010530 (2016).
16. Scaldaferri F, Lopetuso LR, Petito V, et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD United European Gastroenterol. J. 2(2), 113-122 (2014).
17. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics 126(6), 1217-1231 (2010).
18. Putaala H, Salusjarvi T, Nordstrom M, et al. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res. Microbiol. 159(9-10), 692-698 (2008).
19. Alemka A, Clyne M, Shanahan F, Tompkins T, Corcionivoschi N, Bourke B. Probiotic colonization of the adherent mucus layer of HT29MTXE12 cells attenuates Campylobacter jejuni virulence properties. Infect. Immun. 78(6), 2812-2822 (2010).
20. Ahrne S, Hagslatt ML. Effect of lactobacilli on paracellular permeability in the gut. Nutrients 3(1), 104-117 (2011).
21. Adams CA. The probiotic paradox: Live and dead cells are biological response modifiers. Nutr. Res. Rev. 23(1), 37-46 (2010).
22. Kataria J, Li N, Wynn JL, Neu J. Probiotic microbes: Do they need to be alive to be beneficial Nutr. Rev. 67(9), 546-550 (2009).
23. Indriyani A, Juffrie M, Setyati A. Effects of live versus heat-killed probiotics on acute diarrhea in young children. Paediatr. Indones 52, 249-254 (2012).
24. Sawada N, Murata M, Kikuchi K, et al. Tight junctions and human diseases. Med. Electron Microsc. 36(3), 147-156 (2003).
25. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52(7), 988-997 (2003).